Cantargia AB (publ) (STO:CANTA)

Market Cap	974.06M +166.5%
Revenue (ttm)	316.70M
Net Income	146.97M
EPS	0.59
Shares Out	248.61M
PE Ratio	6.64
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,051,677
Average Volume	1,787,974
Open	3.896
Previous Close	3.918
Day's Range	3.848 - 4.372
52-Week Range	1.000 - 6.590
Beta	1.76
RSI	55.30
Earnings Date	May 19, 2026

About Cantargia AB

Cantargia AB (publ), a biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases. The company is developing CAN04 (nadunolimab), an antibody that can bind IL1RAP, which is in phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which is in phase 1 clinical trial for the treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis. It also develops...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 22
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: CANTA